Altogether, these data strongly indicate that persistent high expression levels of ZNF224 could trigger deregulated cell growth and apoptosis resistance in CLL, thus paving the way for the development of anti-ZNF224 therapeutics. Here, ZNF224 is linked to B-cell chronic lymphocytic leukemia.